DMD and Duchenne muscular dystrophy: Given that distinct clock transcriptional outputs are known DMD therapeutic targets [101,154], testing potential synergistic actions of clock-targeting interventions to promote muscle mass, function, regenerative repair, and sarcolemma stability may present unique opportunities for DMD drug development.